AU Patent

AU2013200322B2 — Crystalline solvates and complexes of (1s) -1, 5-anhydro-1-c-(3-((phenyl)methyl)phenyl)-d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes

Assigned to AstraZeneca AB · Expires 2014-09-11 · 12y expired

What this patent protects

Abstract The present invention relates to physical crystal structures of a compound of the formula I: wherein R', R', R2a, R3 and R4 are as defined herein, especially pharmaceutical compositions containing structures of compound I or IT, processes for preparing same, intermediate…

USPTO Abstract

Abstract The present invention relates to physical crystal structures of a compound of the formula I: wherein R', R', R2a, R3 and R4 are as defined herein, especially pharmaceutical compositions containing structures of compound I or IT, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures. OR2a HO \'OH OEt Hd' H0"O "OH

Drugs covered by this patent

Patent Metadata

Patent number
AU2013200322B2
Jurisdiction
AU
Classification
—
Expires
2014-09-11
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.